New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
November 21, 2014
08:28 EDTPBRPetrobras volatility elevated into Q3 and outlook
Subscribe for More Information
06:21 EDTVNOAmazon lease hints at same-day shipping, brick-and-mortar ambitions, WSJ says
Subscribe for More Information
05:59 EDTCATCaterpillar initiated with a Buy at Stifel
Subscribe for More Information
November 20, 2014
13:15 EDTGRMNRaymond James says an outright sale of Garmin is unlikely
Subscribe for More Information
10:37 EDTGRMNOptions with increasing implied volatility
Subscribe for More Information
10:28 EDTPBRPetrobras initiated with a Buy at Deutsche Bank (pre-open)
Subscribe for More Information
09:20 EDTCATCaterpillar reports retail machines sales down 9% in three months end October
Subscribe for More Information
09:05 EDTNKTRNektar presents preclinical study findings for etirinotecan pegol combination
Nektar Therapeutics announced results of a study investigating the preclinical anti-tumor activity and tolerability of etirinotecan pegol in combination with the PARP inhibitor rucaparib in a BRCA1-deficient MX-1 breast tumor model. The preclinical study results demonstrated that all dose combinations of NKTR-102 and rucaparib were well-tolerated, synergistic, and led to 100% prolonged survival in this tumor model. These data were presented during the Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. NKTR-102 and rucaparib in combination exhibited marked synergy, demonstrated by durable complete responses, even at the lowest doses of both agents dosed in combination. The combination of NKTR-102 and rucaparib was tolerated at all dose levels. Doses used in this study provide exposures of NKTR-102 and rucaparib that are achievable clinically, underscoring the translational relevance of these results. Combination studies of NKTR-102 and rucaparib are ongoing in patient-derived xenograft models in collaboration with Professor Paul Haluska at Mayo Clinic and Clovis Oncology.
07:27 EDTGRMNGarmin volatility elevated
Garmin November call option implied volatility is at 40, December is at 35; compared to its 26-week average of 29 according to Track Data, suggesting large near term price movement.
07:11 EDTVNOBofA/Merrill to hold a conference
Subscribe for More Information
05:12 EDTKRCViacom signs 180K-square foot lease at Columbia Square development in Hollywood
Kilroy Realty (KRC) said it has signed a long-term lease with Viacom (VIAB, VIA) for approximately 180,000 square feet of space at KRC’s 685,000-square-foot, mixed-use Columbia Square development located in the heart of Hollywood. The New York-based company plans to relocate and unite the West Coast operations of Viacom media networks including BET, Comedy Central, MTV, Spike TV, VH1 and TV Land currently based in Santa Monica and in other Los Angeles offices into Columbia Square’s 250,000-square-foot Gower Building. The six-story, dual-core glass and steel Gower Building is the larger of two new office buildings totaling 350,000 square feet currently under construction as part of KRC’s $420M mixed-use project located on Sunset Boulevard. Designed by Rios, Clementi, Hale Studios, Columbia Square will also feature 93,000 square feet of renovated, historical creative office and studio space, 30,000 square feet of retail space, 200 luxury residential units and a five-level subterranean parking structure. Viacom is expected to take occupancy in phases starting in late 2016.
November 19, 2014
13:42 EDTVRTXVertex peak CF sales have bullish read from Royalty Pharma bet, TheStreet says
Subscribe for More Information
13:16 EDTGRMNGarmin is an unlikely acquisition target, says Citigroup at Citigroup
Subscribe for More Information
11:32 EDTGRMNGarmin calls active on takeover speculation
Garmin November 57.5 and December 60 calls are active on total call volume of 8,100 contracts (500 puts) on takeover speculation. November call option implied volatility is at 36, December is at 34; compared to its 26-week average of 29 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
10:42 EDTVRTXUBS hosts a conference call with Vertex Pharmaceuticals
Subscribe for More Information
10:25 EDTJCPOptions with decreasing implied volatility
Subscribe for More Information
10:23 EDTGRMNRumor: Garmin strength attributed to takeover speculation
Shares of Garmin (GRMN) are moving higher on speculation Honeywell (HON) has approached the company.
10:00 EDTPBROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Beacon Roofing (BECN) downgraded to Hold from Buy at KeyBanc... BlackBerry (BBRY) downgraded to Underweight from Equal Weight at Morgan Stanley... Consolidated Edison (ED) downgraded to Sell from Neutral at UBS... Denbury Resources (DNR) downgraded to Hold from Buy at Wunderlich... Synchronoss (SNCR) downgraded to Underperform from Neutral at RW Baird... Total System (TSS) downgraded to Sell from Neutral at Goldman... Movado (MOV) downgraded to Market Perform from Outperform at Barrington... Transocean Partners (RIGP) downgraded to Market Perform from Outperform at Wells Fargo... Seadrill Partners (SDLP) downgraded to Market Perform from Outperform at Wells Fargo... Petrobras (PBR) downgraded to Neutral from Buy at UBS.
09:39 EDTPBRActive equity options trading on open
Subscribe for More Information
09:04 EDTJNJJohnson & Johnson submits NDA for three-month paliperidone palmitate
Janssen Research & Development, a Johnson & Johnson company, announced the submission of a New Drug Application, or NDA, for three-month atypical antipsychotic paliperidone palmitate to the FDA. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. If approved, it will be the first and only long-acting atypical antipsychotic that has a four times a year dosing schedule.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use